Profile picture

Professor Jan-Malte Sinning

St. Vinzenz-Hospital, Cologne (Germany)
Membership: FESC Member
Follow
Logo ESC

Contributor content

Discussion and audience interaction
Presentation
Discussion and audience interaction
Which aortic stenosis patients are we not optimally treating?
Presentation
Which aortic stenosis patients are we not optimally treating?
Discussion - What challenges do we need to tackle in the future?
Presentation
Discussion - What challenges do we need to tackle in the future?
Putting severe aortic stenosis patient management into practice.
Presentation
Putting severe aortic stenosis patient management into practice.
2021 ESC/EACTS VHD guidelines: evolution of treatment recommendations.
Presentation
2021 ESC/EACTS VHD guidelines: evolution of treatment recommendations.
Discussion - Patient selection for protected PCI: who benefits most?
Presentation
Discussion - Patient selection for protected PCI: who benefits most?
Reclassification of aortic valve stenosis patients by integration of computed tomography parameters into the echocardiographically assessed continuity equation
Presentation
Reclassification of aortic valve stenosis patients by integration of computed tomography parameters into the echocardiographically assessed continuity equation
Hemodynamic stabilization to facilitate complete revascularization.
Presentation
Hemodynamic stabilization to facilitate complete revascularization.
Next generation transcatheter heart valves improve clinical outcomes in patients undergoing transcatheter aortic valve implantation.
Presentation
Next generation transcatheter heart valves improve clinical outcomes in patients undergoing transcatheter aortic valve implantation.
Transcatheter aortic valve replacement with the self-expanding CoreValve prosthesis performed using clinical best practices: impact on clinical outcomes to six months. The ADVANCE II study.
Presentation
Transcatheter aortic valve replacement with the self-expanding CoreValve prosthesis performed using clinical best practices: impact on clinical outcomes to six months. The ADVANCE II study.

ESC 365 is supported by